Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.52 |
| ▸ | GHSR | Q92847 | 3/20 | 0.51 |
| ▸ | CTSD | P07339 | 1/20 | 0.50 |
| ▸ | TACR2 | P21452 | 5/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.47 |
| ▸ | ITGAV | P06756 | 1/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1598687 | 1.00 | HDAC8 (0.57) | HDAC8HRH3GHSRCTSDTACR2 | |
| SCHEMBL7304234 | 1.00 | HDAC8 (0.57) | HDAC8HRH3GHSRCTSDTACR2 | |
| SCHEMBL8135311 | 0.97 | HDAC8 (0.54) | HDAC8HRH3GHSRCTSDTACR2 | |
| SCHEMBL12148795 | 0.97 | HDAC8 (0.54) | HDAC8HRH3GHSRCTSDTACR2 | |
| Acetic Acid SCHEMBL27525272 | 0.92 | OPRM1 (0.51) | HDAC8HRH3GHSRCTSDITGB3 | |
| SCHEMBL4402175 | 0.90 | HDAC8 (0.48) | HDAC8HRH3GHSRCTSDTACR2 | |
| SCHEMBL4404121 | 0.90 | HDAC8 (0.48) | HDAC8HRH3GHSRCTSDTACR2 | |
| SCHEMBL30637487 | 0.89 | OPRM1 (0.55) | OPRM1OPRD1OPRK1CXCR4 | |
| SCHEMBL30637590 | 0.89 | OPRM1 (0.55) | OPRM1OPRD1OPRK1CXCR4 | |
| SCHEMBL30637599 | 0.89 | OPRM1 (0.55) | OPRM1OPRD1OPRK1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1515684-B1 | CARE AND/OR MAKE-UP COSMETIC COMPOSITION STRUCTURED WITH SILICONE POLYMERS AND ORGANOGELLING AGENTS, IN RIGID FORM | OREAL (FR) | 2010-05-19 | — | — | EP | claimed |
| US-20050245673-A1 | Care and/or make-up cosmetic composition structured with silicone polymers and organogelling agents, in rigid form | L'OREAL S.A. (FR) | 2005-11-03 | — | — | US | claimed |
| EP-4743102-A1 | COLLAGEN PEPTIDE COMPOSITION AND USE THEREOF IN AMELIORATING NEUROLOGICAL CONDITIONS AND FIBROSIS | Rousselot BV (BE) | 2026-05-20 | — | — | EP | disclosed |
| EP-4396306-B1 | A METHOD FOR DECREASING FEED IMPURITIES | NESTE OYJ (FI) | 2025-07-30 | — | — | EP | disclosed |
| US-20240350942-A1 | A METHOD FOR DECREASING FEED IMPURITIES | NESTE OYJ (FI) | 2024-10-24 | — | — | US | disclosed |
| EP-3749738-B1 | VISCOELASTIC, SOLID SURFACTANT COMPOSITION | HENKEL AG & CO KGAA (DE) | 2024-08-14 | — | — | EP | disclosed |
| US-11382911-B2 | Plant extract containing diketopiperazine and method for producing same | SUNTORY HOLDINGS LIMITED (JP) | 2022-07-12 | — | — | US | disclosed |
| CN-107176927-B | Histone demethylase LSD1 inhibitors | 福建金乐医药科技有限公司 | 2020-02-18 | — | — | CN | disclosed |
| US-8524830-B2 | Resin composition and resin molded product | SONY CORPORATION (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8524830-B2 | Resin composition and resin molded product | SONY CORPORATION (JP) | 2013-09-03 | — | — | US | disclosed |
| EP-2308854-A1 | 2,3,6-trisubstituted-4-pyrimidone derivatives | Sanofi-Aventis (FR) | 2011-04-13 | — | — | EP | disclosed |
| EP-1314731-A2 | Substituted pyrimidine compounds and their use | AMGEN INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | AMGEN INC. | 2003-04-17 | — | — | US | disclosed |
| US-20030069425-A1 | Substituted pyrimidine compounds and methods of use | AMGEN INC. | 2003-04-10 | — | — | US | disclosed |
| US-20030008882-A1 | Proteomimetic compounds and methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-01-09 | — | — | US | disclosed |
| WO-2002089738-A2 | PROTEOMIMETIC COMPOUNDS AND METHODS | YALE UNIVERSITY (US) | 2002-11-14 | — | — | WO | disclosed |
| US-6420385-B1 | INFLAMMATORY, PAIN AND DIABETES DISEASES, | AMGEN INC. | 2002-07-16 | — | — | US | disclosed |
| US-6410729-B1 | ANALGESICS; ANTIDIABETIC AGENTS; ANTIINFLAMMATORY AGENTS | AMGEN INC. | 2002-06-25 | — | — | US | disclosed |
| US-6174901-B1 | FOR TREATMENT OF RHEUMATOID ARTHRITIS, PAGETS DISEASE, OSTEOPHOROSIS, MULTIPLE MYELOMA, UVEITITIS, ACUTE OR CHRONIC MYELOGENOUS LEUKEMIA, PANCREATIC .BETA. CELL DESTRUCTION, OSTEOARTHRITIS, RHEUMATOID SPONDYLITIS, GOUTY ARTHRITIS ETC. | AMGEN INC. | 2001-01-16 | — | — | US | disclosed |
| US-6096753-A | Substituted pyrimidinone and pyridone compounds and methods of use | AMGEN INC. (US) | 2000-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008882-A1 | Proteomimetic compounds and methods | PACSIN2, HSP90B1, PHLPP2 | HDAC8 3912/4885HRH3 1706/4885GHSR 3803/4885 |
| US-20030069425-A1 | Substituted pyrimidine compounds and methods of use | DPYD, IL6, IL1B | HDAC8 2312/4885HRH3 2524/4885GHSR 3536/4885 |
| US-20030073704-A1 | Substituted pyridone compounds and methods of use | IL6, IL1B, IL1A | HDAC8 1528/4885HRH3 1708/4885GHSR 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.